Sidoti Csr Weighs in on Balchem’s Q3 Earnings (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Analysts at Sidoti Csr upped their Q3 2025 earnings estimates for Balchem in a research report issued on Monday, April 28th. Sidoti Csr analyst D. Harriman now anticipates that the basic materials company will post earnings of $1.36 per share for the quarter, up from their prior estimate of $1.30. The consensus estimate for Balchem’s current full-year earnings is $4.64 per share. Sidoti Csr also issued estimates for Balchem’s Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $5.15 EPS, Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.39 EPS, Q4 2026 earnings at $1.35 EPS and FY2026 earnings at $5.45 EPS.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Thursday, April 24th. The basic materials company reported $1.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.25 by ($0.03). The company had revenue of $250.52 million during the quarter, compared to analyst estimates of $245.70 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%. The company’s revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.03 earnings per share.

Other analysts have also recently issued reports about the stock. Sidoti raised shares of Balchem to a “hold” rating in a report on Tuesday, February 25th. HC Wainwright set a $180.00 price target on shares of Balchem and gave the company a “buy” rating in a report on Monday. Finally, StockNews.com cut shares of Balchem from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th.

Balchem Trading Down 0.1 %

BCPC opened at $156.01 on Tuesday. The stock has a market capitalization of $5.08 billion, a PE ratio of 39.70, a P/E/G ratio of 4.41 and a beta of 0.75. The firm’s fifty day moving average price is $163.83 and its 200 day moving average price is $166.94. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. Balchem has a 12-month low of $137.69 and a 12-month high of $186.03.

Institutional Trading of Balchem

Institutional investors have recently added to or reduced their stakes in the business. Watts Gwilliam & Co. LLC increased its stake in Balchem by 63.7% during the fourth quarter. Watts Gwilliam & Co. LLC now owns 35,069 shares of the basic materials company’s stock valued at $5,438,000 after purchasing an additional 13,642 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Balchem by 1.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company’s stock worth $80,782,000 after acquiring an additional 7,721 shares during the period. Apollon Wealth Management LLC acquired a new position in Balchem during the 4th quarter valued at about $503,000. Congress Asset Management Co. increased its stake in shares of Balchem by 5.4% in the fourth quarter. Congress Asset Management Co. now owns 317,610 shares of the basic materials company’s stock valued at $51,769,000 after purchasing an additional 16,170 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Balchem by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 370,912 shares of the basic materials company’s stock valued at $60,457,000 after acquiring an additional 8,942 shares during the period. Institutional investors own 87.91% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.